NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/18/2024
Back to search
Official data from USPTO
CELLCARTA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CELLCARTA
ST13
US500000090112472Class
42, 44, 45
Filing
90112472
Registration
7422358
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
06/18/2024
Trademark type
Word
Nice classes
42, 44, 45
Filing date
08/13/2020
Registration date
06/18/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/18/2024
Last transaction
06/18/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2021-03-00
First use in commerce
2021-03-00
Drawing code
4
Owner type
03
Owner location
MONTREAL, QUEBEC, CA
Examiner
LEE, OLIVIA SUNMIN
Law office
O10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CELLCARTA BIOSCIENCES INC.
Caprion Biosciences, Inc.
Representatives
Keith Toms, Esq. MCCARTER & ENGLISH, LLP
Technical classification
Nice Classes
Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific research and development; Medical research and development; Product research and development; Biochemical research and development; Pharmaceutical research and development services; Biomedical research and development services; Design and development of biochemicalpharmaceuticalmedical assays; Scientific and pharmaceutical research in the field of biomarker discovery; Scientific research and development in the fields of bioinformaticsbiomarkersgenomicsproteomicsgenotypingpathologyhistopathology; immune monitoringgenetic profiling for research and development purposes; scientific research and development in the field of mass cytometrycellular analysiscell sortingpathway phenotypingmolecular surface profiling; custom design and development of chemical reagents and biochemical assays; medical laboratory services in the field of pathology; providing laboratory testing services in the fields of bioinformaticsbiomarkersgenomicsproteomicsgenotypingpathologyhistopathology; Conducting clinical trials for others; Conducting clinical trials for others in the fields of pharmaceuticalmedicalscientific research; Consulting services for others in the field of designplanningimplementation project management of clinical trials; Conducting research and clinical trials for others in the fields of oncologyinfectious diseasesautoimmune disordersallergies; Consulting services in the field of clinical trial research; Providing medical and scientific research information in the field of clinical trials; Research and development in the pharmaceutical and biotechnology fields; Laboratory research services relating to pharmaceuticals; Software as a service (SAAS) services featuring software for informaticsbioinformatics; software as a service (SAAS) services featuring software for clinical trial data acquisitionvalidationanalysis; Software as a service (SAAS) services featuring software for cellular analysiscell sortingpathway phenotypingmolecular surface profiling; Software as a service (SAAS) services featuring software for cell cytometry; Software as a service (SAAS) services featuring software for managing information related to clinical trials
Class 44
Genetic testing for medical purposes; Consulting services in the fields of diagnostic medical testing; Medical testing for diagnostic or treatment purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; providing medical information and advice in the fields of pathologypharmacologyimmunology; collectionorganizationanalysisreporting of medical data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; immune monitoringgenetic profiling for medical and diagnostic purposes
Class 45
Regulatory compliance consulting in the fields of pharmaceuticals and clinical diagnostics; Advice and consultancy on fooddrugmedical device regulatory matters; regulatory compliance consulting in the field of obtaining government authorization to market pharmaceuticals and medical device
Publications
History of USPTO decisions and trademark events.
44 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/18/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/13/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/13/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/19/2024
IUAF
USE AMENDMENT FILED
03/18/2024
EISU
TEAS STATEMENT OF USE RECEIVED
03/18/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/20/2023
EX5G
SOU EXTENSION 5 GRANTED
09/19/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/19/2023
EXT5
SOU EXTENSION 5 FILED
09/12/2023
EEXT
SOU TEAS EXTENSION RECEIVED
09/12/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/14/2023
EX4G
SOU EXTENSION 4 GRANTED
03/10/2023
EXT4
SOU EXTENSION 4 FILED
03/10/2023
EEXT
SOU TEAS EXTENSION RECEIVED
03/10/2023
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/01/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/20/2022
EX3G
SOU EXTENSION 3 GRANTED
09/16/2022
EXT3
SOU EXTENSION 3 FILED
09/16/2022
EEXT
SOU TEAS EXTENSION RECEIVED
09/16/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/17/2022
EX2G
SOU EXTENSION 2 GRANTED
03/15/2022
EXT2
SOU EXTENSION 2 FILED
03/15/2022
EEXT
SOU TEAS EXTENSION RECEIVED
03/15/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/18/2021
EX1G
SOU EXTENSION 1 GRANTED
09/16/2021
EXT1
SOU EXTENSION 1 FILED
09/16/2021
EEXT
SOU TEAS EXTENSION RECEIVED
09/16/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/16/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/19/2021
PUBO
PUBLISHED FOR OPPOSITION
01/19/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/30/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/14/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
12/11/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/11/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
12/11/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/11/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/09/2020
GNRT
NON-FINAL ACTION E-MAILED
12/09/2020
CNRT
NON-FINAL ACTION WRITTEN
12/09/2020
DOCK
ASSIGNED TO EXAMINER
12/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/17/2020
NWAP
NEW APPLICATION ENTERED
08/17/2020
Continuous trademark protection
Get notified about every new filing that threatens CELLCARTA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.